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Management of acute allergic 
reactions to food 
There are no recommended medications for the 
prevention of immunoglobulin E (IgE)-mediated, 
non-IgE-mediated or mixed food-induced allergic 
reactions.[1,2] Medication may, however, be used to treat both severe and 
non-severe allergic reactions. While treating mild-to-moderate food 
allergic reactions, the patient should be closely monitored for any signs 
or symptoms of an anaphylactic reaction.
Anaphylaxis may be fatal if not recognised and managed 
appropriately with rapid treatment. The drug of choice for the 
treatment of an anaphylactic reaction is intramuscular adrenaline, 
with other drugs given as adjuctive therapy.[3,4] In cases of suboptimal 
response to the initial dose of adrenaline, or with progression of 
symptoms, a repeat dose should be given.[5] Basic cardiopulmonary 
resuscitation should be initiated and maintained to support the 
airway, oxygenation and circulation. The following steps should be 
instituted in the initial management of anaphylaxis:
• eliminate additional exposure to the allergen
• administer intramuscular injection(s) of adrenaline
• call for help
• place the patient in a recumbent position, with lower limbs 
elevated, and do not allow the patient to stand up quickly 
• give supplemental oxygen
• administer intravenous fluid in cases of hypotension or incomplete 
response to intramuscular adrenaline
• administer adjunctive therapy (antihistamines and corticosteroids)
• admit the patient for close observation for biphasic reactions
•  instigate or review risk-reduction strategies after an anaphylactic 
episode.
Adrenaline is the drug of choice as first-line management of 
anaphylaxis. There are no absolute contraindications to treatment 
with adrenaline.[4,6] It should be administered intramuscularly (not 
subcutaneously) at a dose of 0.01  mg.kg-1 (0.01  mL/kg of ‘neat’ 
adrenaline; maximum 0.5  mL) in the mid-anterolateral thigh to 
achieve peak tissue and plasma concentrations rapidly.[1] 
Adrenaline auto-injectors (e.g. EpiPen) are more convenient 
options than ampoules and syringes, which may be difficult to use 
quickly or accurately – especially by parents or patients in emergency 
situations. EpiPen injectors are available containing fixed doses of 
0.15 mg and 0.30 mg adrenaline.[7]
H1 antihistamines may be used to decrease skin symptoms (itch, 
flush and urticaria) and nasal symptoms (rhinorrhoea and congestion) 
and are therefore beneficial in children and adults with non-life-
threatening manifestations of food allergy. H1 antihistamines cannot 
prevent or treat life-threatening manifestations of anaphylaxis.[8] They 
are, however, used as adjunctive therapy to adrenaline. Less-sedating 
oral second-generation antihistamines are preferred to sedating first-
generation antihistamines.[9] Intravenous antihistamines should be 
used if oral medication is not tolerated or contraindicated. 
Corticosteroids are often used in anaphylaxis, but they have a 
delayed mechanism of action and are not useful during an acute 
episode. However, their anti-inflammatory properties may make 
them suitable as adjunctive therapy to reduce the risk of biphasic 
reactions.[1,5] 
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An anaphylactic reaction may be fatal if not recognised and managed appropriately with rapid treatment. Key steps in the management of 
anaphylaxis include eliminating additional exposure to the allergen, basic life-support measures and prompt intramuscular administration 
of adrenaline 0.01  mg/kg (maximum 0.5  mL). Adjunctive measures include nebulised bronchodilators for lower-airway obstruction, 
nebulised adrenaline for stridor, antihistamines and corticosteroids. Patients with an anaphylactic reaction should be admitted to a medical 
facility so that possible biphasic reactions may be observed and risk-reduction strategies initiated or reviewed after recovery from the acute 
episode.
Factors associated with increased risk of severe reactions include co-existing asthma (and  poor asthma control), previous severe 
reactions, delayed administration of adrenaline, adolescents and young adults, reaction to trace amounts of foods, use of non-selective 
β-blockers and patients who live far from medical care. 
Risk-reduction measures include providing education with regard to food allergy and a written emergency treatment plan on allergen 
avoidance, early symptom recognition and appropriate emergency treatment. Risk assessment allows stratification with provision of 
injectable adrenaline (preferably via an auto-injector) if necessary. Patients with ambulatory adrenaline should be provided with written 
instructions regarding the indications for and method of administration of this drug and trained in its administration. Patients and their 
caregivers should be instructed about how to avoid foods to which the former are allergic and provided with alternatives. Permission must 
be given to inform all relevant caregivers of the diagnosis of food allergy. The patient must always wear a MedicAlert necklace or bracelet 
and be encouraged to join an appropriate patient support organisation.
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The initial pharmacological management of 
anaphylaxis is given in Table 1. 
Co-factors for reactions
A number of co-factors may augment or amplify 
the severity of allergic reactions.[12] Given their 
importance in eliciting anaphylaxis, these 
co-factors need to be included in diagnostic 
measures and management. They include 
the following:
• Physical exercise. Food-dependent exercise-
induced anaphylaxis may occur if exercise 
and consumption of a certain food occur 
within 4 hours of each other. The implicated 
food is usually well tolerated when the patient 
does not exercise.
• Medication includes non-steroidal anti-
inflammatory drugs, such as aspirin, 
ibuprofen and opiates.[13]
• Alcohol.[14]
• Fever and infectious diseases.[15]
• High-pollen season. In oral allergy 
syndrome, symptoms may be heightened 
during pollen season.
Although an anaphylactic reaction seems to 
be triggered by a sole allergen in most cases, 
exposure to a single allergen is sometimes not 
enough to trigger an episode. Concomitant 
exposure to a combination of allergens, 
infections, physical exercise, psychological 
stress, alcohol and/or concomitant medi-
cation are necessary to provoke a reaction, 
i.e. summation anaphylaxis.
Risk factors associated 
with the severity of 
allergic reactions to 
foods
The severity of allergic reactions to food 
allergens is multifactorial and variable. The 
severity of any reaction cannot be accurately 
predicted by the degree of the severity of any 
previous reaction, or by the size of the wheal 
of a skin-prick test or level of specific IgE. 
Factors associated with increased risk, 
as shown in epidemiological studies,[16-24] 
include co-existing asthma (and poor asthma 
control), previous severe reactions, delayed 
administration of adrenaline, adolescents and 
young adults, reaction to trace amounts of 
foods, use of non-selective β-blockers and 
patients in remote areas far from medical care. 
Self-injectable adrenaline is under-used, even 
when available, and incorrect administration 
may also be an important factor, particularly 
when administered by needle and syringe 
rather than by an auto-injector.[4]
Risk reduction[25]
The following factors should be considered 
in reducing the risk of an allergic reaction:
• Education with regard to food allergy 
and provision of a written emergency 
treatment plan on allergen avoidance, early 
symptom recognition and appropriate 
emergency treatment.
• Risk assessment and stratification 
with provision of injectable adrenaline 
(preferably via an auto-injector) if 
necessary. Training and provision 
of written instructions with regard 
to the indications for and method of 
administration of adrenaline.
• Follow-up with a primary care physician. 
Primary caregivers, nurses and doctors 
should be adequately trained and receive 
education to identify and treat allergic 
reactions to food early.
• Referral to an allergist if first presentation 
or unknown cause. More complicated 
food allergic patients should be referred 
to medical professionals competent in the 
diagnosis and management of food allergy.
• Management of patients with severe, 
complex or multiple food allergies by a 
multidisciplinary team, including dieticians 
and medical professionals.
• Early allergy testing in patients with food 
allergy symptoms. Interpretation of food 
allergy tests by a practitioner skilled in 
food allergy and with access to food 
challenge testing for cases of inconclusive 
results.
• Patients and caregivers should be educated 
about foods that should be avoided and 
available alternatives.
• Patients should be instructed to read 
labels. Clear guidelines should be set for 
labelling foodstuffs, including products 
that should be clearly linked to the name 
of an allergen to avoid confusion.
• Permission should be obtained to 
communicate the diagnosis of food 
allergy to all relevant caregivers, 
including schoolteachers. The patient 
must always wear a MedicAlert necklace 
or bracelet. 
• Patients should be encouraged to join an 
appropriate patient support organisation.
Table 1. Initial pharmacological management of anaphylaxis[1]
First-line treatment
Adrenaline IM, 1:1 000 solution
Adrenaline dose might need to be repeated every 5 - 15 minutes
Via needle and syringe: adrenaline (undiluted 1:1 000 concentration) IM, 0.01 mg/kg per dose 
(equivalent to 0.01 mL/kg); maximum 0.5 mg/dose in the anterolateral thigh
Auto-injectors
Weight 8 - 25 kg: 0.15 mg IM in the anterolateral thigh[10,11]
Weight >25 kg: 0.3 mg IM in the anterolateral thigh[10,11] 
Adjunctive treatment
Bronchodilators (β2-agonist): salbutamol or fenoterol by metered-dose inhaler or nebulisation 
for lower-airway obstruction
Inhaled nebulised adrenaline for upper-airway obstruction
H1 antihistamine
Corticosteroids
IM = intramuscularly.
Table 2. Indications for the prescription of self-injectable adrenaline devices in the 
community[14]
Absolute indications
Previous anaphylactic reaction to a food, insect sting, latex or unavoidable aeroallergen
Co-existent unstable or moderate-to-severe persistent asthma and food allergy 
Idiopathic anaphylaxis
Food-dependent exercise-induced anaphylaxis
Relative indications
Mild-to-moderate peanut/and or tree nut allergy in patients ≥5 years of age 
Food allergy in a teenager or young adult
Far from a medical facility
Reactions to small amounts of food, such as air-borne food allergens or contact via skin only
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Indications for the prescription of self-injectable adrenaline devices 
in the community are given in Table 2. 
Food allergy education
Strict avoidance of allergens
• Strict avoidance of allergens is the cornerstone of allergy 
management, although it is not curative and leaves patients at risk 
for accidental exposure. 
• Only foods to which the patient is allergic should be avoided.
• Patients should receive education about label reading and medical 
terminology related to the identification of allergens.
• Patients should receive instruction with regard to cross-reactive 
allergens.
• It is advisable to involve a dietician in formulating a nutritionally 
adequate, allergen-free diet, especially in cases of multiple food 
allergy. 
• Information on how to minimise cross-contact of foods with an 
allergen during meal preparation and serving can help to prevent 
accidental ingestion and reactions.
• Education on high-risk accidental ingestion, especially of foods 
prepared away from home (e.g. eating out, visiting friends’ homes, 
or attending parties).
Early recognition of allergic reactions and anaphylaxis
• A written emergency plan should be given to the patient; their 
caregivers should be notified about the food allergy and given a 
copy of the plan. Plans are available at http://www.allergysa.org.
• The emergency plan should contain an image clearly differentiating 
between mild reactions and reactions requiring the use of adrenaline.
• Antihistamines are used for the management of non-severe allergic 
reactions.
• When only antihistamines are used for the treatment of acute 
allergic reactions, patients should be monitored should they 
develop more severe symptoms.
• As soon as a patient has an anaphylactic reaction, they should be 
placed in the supine position with lower extremities elevated; they 
should not stand up and move as this has been reported to increase 
the risk of severe anaphylaxis or sudden death.
• Adrenaline should be administered for all reactions that exceed the 
threshold in the action plan. If the patient or caregiver is considering 
using adrenaline, it is usually safer to give it immediately rather than 
to wait until definitive signs or symptoms appear.
• A MedicAlert bracelet or necklace should be provided to all 
patients at risk of anaphylaxis.
Provision of an emergency kit, including self-injectable 
adrenaline and intravenous antihistamine
• Adrenaline is the mainstay of treating anaphylaxis.
• Giving adrenaline via an auto-injector is preferable to administering 
it via a needle and syringe.
Provision of instructions on when to go to a medical 
facility 
• Patients should be informed when to go to a medical facility if they 
are experiencing symptoms of an anaphylactic reaction.
• For patients with a history of severe allergic reactions, adrenaline 
should be administered at the onset of mild symptoms; then they 
should proceed to an emergency facility.
• Patients experiencing an anaphylactic episode should be observed 
in a medical facility for at least 12 - 24 hours because of the risk of 
biphasic reactions.
Educate patients about long-term ongoing management
• Long-term management must include at least an annual medical 
review to assess accidental ingestion, reactions, or both, nutritional 
adequacy of their diet, approaches to allergen avoidance and need 
for retesting for resolution of food allergy.
• At each visit, risk assessment for asthma, re-education about 
early recognition and emergency treatment plans should be 
reviewed.
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